The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C Ups Risk of Kidney Cancer

Back to News Homepage

Next

Experimental Polymerase Inhibitor Lowers HCV Viral Load Fast

Early HCV Study Outcome: PSI-7977

April 19, 2010

Print this page

Learn about the mid-trial results of PSI-7977’s effectiveness against Hepatitis C.

Pharmasset jumps on hepatitis C study results

PRINCETON, N.J.

Pharmasset Inc. on Thursday reported promising early results from a clinical trial of a hepatitis C drug candidate.

The company is testing a drug candidate called PSI-7977. In the midstage trial, a group of 63 hepatitis C patients are being treated with a combination of PSI-7977 and two older drugs, Pegasys and Copegus, or Pegasys and Copegus alone. None of the patients have received any previous treatment for the disease.

Continue reading this entire article:
http://www.businessweek.com/ap/financialnews/D9F3JTC00.htm

No Comments - be the first!
Share
Share

Previous

Hepatitis C Ups Risk of Kidney Cancer

Back to News Homepage

Next

Experimental Polymerase Inhibitor Lowers HCV Viral Load Fast

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.